Related Experiment Video

Updated: Jul 6, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

ERbeta: a novel estrogen receptor offers the potential for new drug development

S Nilsson1, G Kuiper, J A Gustafsson

  • 1Karo Bio AB, Huddinge, Sweden.

Trends in Endocrinology and Metabolism: TEM
|April 15, 2008
PubMed

Insights

Developing selective estrogen therapies targeting estrogen receptors alpha and beta offers new hope for treating various conditions in women and potentially men. This approach aims to minimize unwanted side effects while maximizing benefits.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Estrogen therapy presents challenges due to multiple target organs and side effects.
  • Developing tissue-selective estrogen receptor modulators is crucial for improved drug therapy.
  • The discovery of two distinct estrogen receptors, ERalpha and ERbeta, offers new therapeutic avenues.

Purpose of the Study:

  • To explore the potential of novel, tissue-selective estrogens.
  • To leverage the unique tissue distribution of ERalpha and ERbeta for targeted therapies.
  • To identify future therapeutic applications for selective estrogen modulation.

Main Methods:

  • Review of current knowledge on estrogen receptor (ERalpha and ERbeta) tissue distribution.
  • Analysis of differing actions of ERalpha and ERbeta on specific genes.
  • Evaluation of potential therapeutic targets based on receptor distribution.

Main Results:

  • ERalpha and ERbeta exhibit distinct tissue distributions and actions.
  • This distinctness provides a basis for developing tissue-selective estrogen therapies.
  • Selective therapies show promise for conditions like menopausal symptoms, osteoporosis, cardiovascular disease, type II diabetes, Alzheimer's disease, and urinary incontinence.

Conclusions:

  • Development of selective estrogen therapies targeting ERalpha and ERbeta is achievable.
  • These therapies hold promise for treating a range of conditions in women.
  • Potential benefits may extend to men as well.

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...